~~<i id='A9117ACA64'><strike id='A9117ACA64'><tt id='A9117ACA64'><pre id='A9117ACA64'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

fashion

author：knowledge 2025-09-28 04:58:54 - browse：1

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： AstraZeneca, Daiichi breast cancer treatment succeeds in trial

hotspot

focus

knowledge

focus

hotspot

knowledge

Theparentsofthesemousepupswereasame-sexcouple.Anewassisted-reproductionprocesscouldsomedaymakethatpo

WSS

Thermo Fisher plant for manufacturing gene therapies to expand

Emergency workers more likely to restrain Black patients: study

Ukraine and a new approach to mental health in war

Emergency workers more likely to restrain Black patients: study

Stop the failed accountable care organization experiment

CDC advisers recommend seasonal use of Pfizer RSV shot

explore

fashion

hotspot

What does generative AI mean for health care? We asked experts

CDC advisers recommend seasonal use of Pfizer RSV shot

Novavax promises a turnaround & Lilly roils the obesity market

Nurses recount patients attacks

After affirmative action ruling, medical educators look to 'holistic review'

CVS Caremark has created a new ploy: the drug ‘rebate credit’

DIEP, the 'gold standard' of breast reconstruction, is under threat

Biotech lab space demand falls sharply

Peter Hotez and the public health issue of online harassment

STAT Virtual Event: Putting AI to the Test

focus

Stop the failed accountable care organization experiment

Health AI adoption puts security, privacy startups on investors' radar

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Drug for rare kidney disease narrowly misses mark in clinical trial

Senate HELP committee spars over health care workforce policies

It's been 20 years since Dolly the sheep. Where's my clone?

knowledge

focus

hotspot

knowledge